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Background: Despite the importance of identifying and managing a pulmonary exacerbation, and its use as an outcome measure in interventions,
there is no standardised deﬁnition in cystic ﬁbrosis. In achieving standardised criteria it is important to identify patient-reported indicators.
Methods: Interviews were undertaken with 35 school aged children. They reported symptoms experienced during a pulmonary exacerbation in two
ways: the ﬁrst symptoms they become aware of, and how they recognised when they were improving. Interviews were taped, transcribed verbatim
and the data analysed thematically.
Results: For many children, the onset of an exacerbation was characterised by ‘cold’ symptoms, tiredness, and changes in cough. For those with
moderate or severe disease, sleep disruption, activity induced breathlessness, changes in mood, sputum volume and lack of appetite were common.
When describing improvement children focused initially on activities they were now able to perform accompanied by improvements in tiredness
and cough. Those with moderate or severe disease also reported improvements in sleep and mood, breathlessness, sputum volume and colour.
Conclusions: Child-reported indicators of a pulmonary exacerbation tend to map onto those reported by adults. These results provide the rationale
for the development of a single scale for school age children and adults that could be sensitive to progressive stages of CF disease.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pulmonary exacerbation; Respiratory symptoms; Patient-reported outcome1. Introduction
Pulmonary exacerbations (PE) are a prominent characteristic
of cystic fibrosis (CF) disease. They are associated with a poor
health-related quality of life [1,2] disease progression [3] and
survival [4]. Therefore, it is essential that exacerbations of pul-
monary symptoms are recognised by the patient, diagnosed and
the severity determined by the clinician [5], early appropriate
treatment initiated, and the course of the exacerbation and re-
sponse to treatment assessed.
Despite the importance of identifying and managing a pul-
monary exacerbation, and its use as an outcome measure in☆ Data presented at the 33rd ECFS Conference, Valencia, Spain (2010).
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doi:10.1016/j.jcf.2011.11.005interventions, there is no standardised definition in CF. In an
Australian survey there was a lack of consensus among clini-
cians who managed CF patients as to the variables considered
when diagnosing a pulmonary exacerbation. Clinicians agreed
with only half of the listed signs, symptoms and investigations
derived from definitions used in published research studies [6].
Furthermore, when diagnosing a PE clinicians who managed
both children and adults rated over 20% of signs and/or symp-
toms as having different levels of importance [6].
Some attempts have been made to establish clear criteria in
CF with the use of scoring systems [7–12] but there is a lack
of consistency across scales [6,13,14]. From a combined poolre, Preston, PR1 2HE, UK. Tel.: +44 1772 893790.
by Elsevier B.V. All rights reserved.
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cough (cough/frequency and/or day/night cough) were assessed
on all eight scales. Seven of the eight scales assessed sputum
production and/or volume and five included decreased appetite.
Furthermore, the rationale for including symptoms in scales
was not always clear and no scale has undergone appropriate
clinimetric evaluation.
As part of the process of achieving standardised criteria it is
important to clearly identify patient-reported indicators of a
pulmonary exacerbation for different levels of disease severity.
Gaining information directly from children and adults is a sensi-
ble way forward given that a clinician's diagnosis of a PE is
heavily influenced by patient reports. Asking the patient is noth-
ing new, but such information can be used to provide a formal,
standardised, valid and reliable way of gaining the patients' per-
spective as to the factors that constitute a PE, and supply infor-
mation not captured by other means as there are some things that
only the patient can know (for example, fatigue and nausea).
Little data have been collected directly from children or
adults with CF concerning pulmonary exacerbations. Data
used to develop the symptom scales on the CF-specific quality
of life instruments [15–19] go someway towards this but their
original purpose was not to identify an exacerbation. A promis-
ing scale is being developed and evaluated in the US [20]. This
is a patient-derived respiratory symptom assessment and the ra-
tionale for the inclusion of symptoms has been based on quali-
tative work. Twenty-five interviews (13 children and 12 adults)
using the Day Reconstruction Method (based on symptoms
from the previous day) and 9 cognitive interviews were undertak-
en. Thematic analysis of the data enabled the development of a 16
item daily symptom diary (cough, chest tightness, difficulty
breathing, wheeze, coughing up mucus, fever, chills/sweats, fa-
tigue, sleep, school/work attendance, reduction in activities,
more time sitting/lying down, worry, frustration, sad/depressed
and cranky). The importance of qualitative work is often underva-
lued but it is essential to generate accurate patient-reported
information.
Likewise, interviews were undertaken with 49 adults with
CF in the UK [21]. This was a purposefully selected sample
with representation from key demographic and clinical vari-
ables. Participants were asked to report symptoms experienced
during a pulmonary exacerbation in twoways: the first symptoms
they become aware of, and how they subsequently recognised
when they were improving. A range of systemic and respiratory
symptoms were reported and their relative importance varied by
severity of disease. For many patients the onset of an exacerba-
tion was characterised by fatigue and changes in sleep, cough,
sputum, appetite, mood and daily activities. Those with mild dis-
ease typically reported ‘cold’ symptoms whereas those with se-
vere disease found it more difficult to recognise the onset of an
exacerbation. They typically reported greater levels of fatigue
(e.g. sleeping during the day), greater effort required to cough
and breathe, nausea/vomiting (related to sputum/cough) and
chest pain. An improvement was primarily described in terms
of the activities they were able to perform (e.g. return to work,
shopping) followed by improvements in fatigue, sleep, sputum,
cough and mood. This current work reports on interviews withchildren employing similar methodology and analyses. It aimed
to (a) identify the salient characteristics of a pulmonary exacerba-
tion as reported by school aged children with cystic fibrosis and
(b) examine whether their descriptions of a pulmonary exacerba-
tion map onto the results from adults.
2. Methods
2.1. Sampling
School aged children with cystic fibrosis were recruited
from two specialist CF Centres in the UK. Purposive sampling
ensured representation of key variables including age, gender,
CF FEV1 percentiles, nutritional status, microbiology, number
of clinically recorded exacerbations requiring hospital admis-
sion or home IV treatment in the past year and whether the
child was experiencing an exacerbation at the time of interview.
All exacerbations had been diagnosed by a CF paediatrician
and defined clinically as a change in symptoms not responding
to outpatient therapy. Symptoms included increased cough, fa-
tigue, volume and colour of sputum, and/or decreased activity
and weight loss. The treatment protocol for exacerbations was
generally two IV antibiotics, increased physiotherapy and atten-
tion to nutrition where needed.
Thirty-eight children were invited to take part in the study,
all of whom had experience of pulmonary exacerbations.
Those children experiencing an exacerbation at the time of in-
terview were being managed in hospital and were interviewed
towards the end of their treatment. For outpatients, FEV1 was
measured at the clinic visit at which the interview took place.
For those hospitalised with an exacerbation, FEV1 was recorded
on the day of discharge. The study was approved by the North
Staffordshire Local Research Ethics Committee. Both parental
and child consent/assent were obtained.
2.2. Conceptual approach, interviews and data analysis
Interviews were undertaken by a single researcher (A Holt).
A semi-structured interview format was used which allowed the
child flexibility to follow their own experiences and also for the
researcher to probe areas of interest [22]. Children were asked
to report symptoms experienced during a pulmonary exacerba-
tion. They were asked to report the first symptoms they become
aware of, and how they subsequently recognised when they
were improving. Parents of children under 12 years were allowed
to provide information in the interviews but the experiences and
perceptions of the children were always elicited first.
A grounded theory approach utilizing constant comparative
analysis [23] was employed. The interview schedule was
amended as new concepts emerged from ongoing analysis. This
provided systematic prompts to ensure focused and appropriate
questioning around children's experiences of pulmonary exacer-
bations. Interviews were taped, transcribed verbatim and the data
analysed thematically. A rigorous method of working through the
interview transcripts was devised as were methods of coding and
categorizing the data. Data collection and coding took place con-
currently. Line by line coding of the transcripts was undertaken.
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These codes were then grouped into conceptual categories
[24,25]. Validity checks were maintained throughout the analysis
by checking and rechecking the emerging categories. This entire
process was conducted manually. Furthermore, this was done in-
dependently by two researchers (JA, A Holt) to ensure that com-
parable interpretations were being made. Where discrepancies
existed, the coding of concepts and categories were agreed
following a multidisciplinary team consensus.
2.3. Categorization of disease severity
Definitions of disease severity, based on Knudson reference
equations (mild disease: FEV1≥70% predicted, moderate dis-
ease: FEV1 40–69% predicted, and severe disease: FEV1 b40%
predicted) are typically used in CF research and clinical practice
[26]. This categorization of disease severity may be acceptable
for adults but the reference equations on which they are based
are known to have low predictive accuracy in short and young
children [27]. Kulich et al. have developed CF-specific reference
equations that describe the distribution among people with CF in
terms of percentiles of FEV1 for a given height, age and sex [28].
CF FEV1 percentiles were used to categorize disease severity in
this study. Descriptions of symptoms were investigated for
three disease severity groups: mild disease (CF FEV1 percentiles
≥70), moderate disease (CF FEV1 percentiles 30–69) and severe
disease (CF FEV1 percentiles b30).
A further objective of the work was to examine whether chil-
dren's descriptions of a pulmonary exacerbation map onto
those of adults. It was essential that the mild, moderate and se-
vere disease categories were broadly compatible between adults
and children. However, the published adult data categorized
disease severity using Knudson reference equations. To test
the validity of comparing the adult and child results, the origi-
nal adult data was calculated to determine CF FEV1 percentiles
and categorized in the same way as the child data. This was
checked to see if each individual remained in their original dis-
ease severity category (based on Knudson equations). The vast
majority of the 47 adults remained in their original mild, moder-
ate and severe disease groupings. The exceptions were a 17 year
old male (FEV1% predicted 48) who moved from the moderate
to severe disease group (CF FEV1 percentile 17), and 2 borderline
cases. A 25 year old male with an FEV1 percent predicted of 68%
who was originally classed as having moderate disease just
slipped into the mild category (CF FEV1 percentile 71), and a
25 year old female with an FEV1 percent predicted of 72% orig-
inally classed as mild just slipped into the moderate disease cate-
gory (CF FEV1 percentile 68). CF FEV1 percentiles can only be
calculated for people up to 40 years of age therefore a recalcula-
tion could not be performed for a 47 year old female. On the basis
of these findings, comparisons between mild, moderate and se-
vere disease groups for children and adults were considered valid.
3. Results
Thirty-five children aged between six and 15 years agreed to
be interviewed. Three parents refused to consent (parental lackof time=2; just participated in another study=1). The charac-
teristics of the sample are given in Table 1, with key variables
featured for each disease severity group. A range of systemic
and respiratory symptoms were experienced during a pulmonary
exacerbation. The first symptoms the children become aware of
and their frequency are presented in Table 2 for the three disease
severity groups. For comparison, Table 2 also incorporates data
previously reported from the UK adult sample (FEV1 based on
Knudson equations) [21]. Reports of those experiencing an exac-
erbation at the time of interview and those who were well were
analysed thematically. Similar symptoms of an exacerbation were
reported regardless of their clinical status when reporting.
For many children the onset of an exacerbation was charac-
terised by tiredness, changes in cough and ‘cold’ symptoms
(runny nose, sore throat, general body aches and feeling generally
unwell). For those with moderate or severe disease these symp-
toms were typically accompanied by sleep disruption (predomi-
nantly due to coughing), activity induced breathlessness and
mood. Those with severe disease also reported changes in sputum
volume and lack of appetite. The child-reported indicators of a
pulmonary exacerbation tended to map onto those reported by
adults [21]. There were a couple of notable exceptions. Children
with mild disease were less likely to report producing sputum or
changes in the amount, viscosity or colour of sputum than their
peers with more advanced disease, or adults with mild disease.
Whereas the vast majority of adults reported changes in sputum
viscosity and colour, for children, there were incremental reports
of sputum changes with incremental levels of disease severity.
Furthermore, children with mild or moderate disease were less
likely to report decreased appetite than adults with similar levels
of disease severity. As disease severity increased the reporting of
‘cold’ symptoms (runny nose and sore throat) decreased for both
children and adults.
Reported symptoms that defined improvement and their fre-
quency are presented in Table 3, together with adult data for
comparison [21]. When describing improvement from an exacer-
bation, the majority of children initially focused on activities that
they hadmissed andwere now able to perform again, such as play-
ing outside the house, playing/‘hanging out’ with friends, concen-
trating on school work or computer games, accompanied by
improvements in tiredness and cough. Those with moderate or se-
vere disease also reported improvements in sleep and mood.
Those with severe disease reported additional improvements in
breathlessness, sputum volume and colour. Child reported im-
provement in symptoms largely mapped onto those reported by
adults [21]. Consistently, the notable exceptions were changes in
sputum and appetite. It is noteworthy that the salient indicators
of a pulmonary exacerbation and subsequent improvement were
most similar for children and adults with severe disease.
4. Discussion
The purpose of this work was to contribute to the ongoing
discussion on defining a pulmonary exacerbation in CF disease.
The child-reported indicators of a pulmonary exacerbation tended
to map onto those reported by adults. There were a couple of nota-
ble exceptions. Children with mild or moderate disease were less
Table 1
Characteristics of the sample (n=35). Mean age, CF-Specific FEV1 percentiles, and numbers of children with key variables for each disease severity group.
Mild Moderate Severe All children
(CF-FEV1 percentiles ≥70) (CF-FEV1 percentiles 30–69) (CF-FEV1 percentiles b30) N=35
N=11 N=13 N=11
Age (mean years, range) 12.78 (10–15) 12.60 (9–15) 10.56 (6–15) 12.0 (6–15)
CF-Specific FEV1 percentiles (mean, range) 84.6 (70–97) 52.3 (33–68) 14.67 (4–29) 54.6 (4–97)
Gender 3 M, 8 F 8 M, 5 F 6 M, 5 F 17 M, 18 F
Recorded exacerbations in past year (mean, range) 1.22 (0–4) 0.9 (0–3) 4.33 (0–12) 2.3 (0–12)
Time since last exacerbation (mean months, range) 10.8 (0–22) 5.5 (0–18) 2.8 (0–14) 6.1 (0–22)
Cystic fibrosis related diabetes (n) 1 0 2 3
Enteral tube feeds (n) 3 2 5 10
Oral supplements (n) 3 2 7 12
Venous access device (n) 3 5 7 15
P. aeruginosa [chronic infection] (n) 1 2 3 6
B. cepacia complex [chronic infection] (n) 0 0 2 2
Experiencing exacerbation at time of interview (n) 4 6 7 17
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the amount, viscosity or colour of sputum. However, both children
and adults categorized as having severe disease reported very sim-
ilar symptoms of an exacerbation and subsequent improvement.
Illness cognition and behaviour are important factors to consid-
er. Knowing how patients recognise when their chest is deterio-
rating may help us to inform them when to seek medical advice
and secure early diagnosis. Adult patients have their own ‘barom-
eters’ as to when to seek help [20] and many children and adults
[21] in our work described ‘putting up’ with symptoms if they
were still able to function physically. Only when this functioning
was affected did they seek medical attention. Work that focuses
on the early detection of an exacerbation by patients and parents
is needed to aid early intervention, relieve symptoms and main-
tain pulmonary function. A limitation of this work was that data
from parents was not independently recorded and analysed. How-
ever, parents of younger children tended to add extra information
that the child had forgotten or omitted.
It is significant that both children and adults with CF predomi-
nantly focus on respiratory symptoms and how they feel when
asked to identify the initial symptoms of a pulmonary exacerbation
(for example, tiredness, cough, sputum, breathlessness). However,
when asked how they recognise when they are improving a good
deal of the discussion focused on what they were now able to
do. For example, go to school and afterschool clubs/activities,
concentrate on computer games, meet their friends and engage in
activities outside of the house. This is important as it indicates that
patient-reported outcome measures may be more sensitive if they
include indicators of ‘activity’ as well as items of respiratory
symptomatology. When questioned as to why they were now
able to engage in these activities the responses were overwhelm-
ingly due to a reduction in tiredness and respiratory symptoms.
Nevertheless, for children and adults with CF an increase in their
daily physical activities was the predominant way in which they
described their improvement.
These data have implications for developing standardised
and valid criteria of a pulmonary exacerbation and the develop-
ment of patient-reported tools. If the occurrence of, or number
of, pulmonary exacerbations constitute a primary outcomemeasure in clinical trials it is crucial for exacerbations to be
clearly and meaningfully defined by both patients and health
professionals. Our work supports the inclusion of ‘activity im-
pacts’ in the measure being developed and evaluated by Goss
et al. [20]. It is also noteworthy that patient-reported physical
functioning has been shown to predict survival in CF [29].
The use of CF-reference equations is a promising way for-
ward. It makes clinical sense to place an individual's lung func-
tion in the context of others with CF rather than a healthy
reference population. It is argued that the use of CF-FEV1 per-
centiles strengthened this work as a more clinically meaningful
categorization of disease severity could be established for chil-
dren. For example, if Knudson equations had been employed
none of the children would have been categorized as having se-
vere disease because no child had an FEV1 % predicted of less
than 40%. Yet, it is likely that a seven year old boy with an
FEV1 % predicted of 60% or a 10 year old girl with an FEV1 %
predicted of 45% would be viewed as having severe CF disease.
The use of CF-reference equations in children and adults would
make it easier to follow the individual longitudinally and provide
an important context to better understand lung function.
A strength of this work is that the findings have been derived
from a total of 84 interviews based on carefully selected child and
adult samples with representation from key demographic and
clinical variables. They provide patient-generated information
to aid the early detection of, and recovery from, a pulmonary ex-
acerbation for children and adults with different levels of disease
severity. However, the results are based on data from two UK CF
Centres and a wider geographical representation is required to en-
sure validity. Large samples employing quantitative methods are
required to further explore these results. A UK Delphi study is
currently in progress, seeking to establish a consensus among
CF health professionals and adult patients as to what defines a
PE. Together with the current and previous findings [e.g.
6,20,21], the UK Delphi data should also add to the ongoing de-
bate as to what defines a pulmonary exacerbation in CF.
An international effort is required to move this issue for-
ward. The ultimate goal is to develop an internationally agreed
definition of a pulmonary exacerbation and subsequent scoring
Table 2
First patient-reported symptoms of a pulmonary exacerbation by disease severity (most common phrases patients used to describe symptoms). Adult data previously reported are inserted for comparison [21].
Mild Moderate Severe
Children: CF FEV1 percentiles ≥70
(Adults — FEV1 % pred ≥70)
Children: CF FEV1 percentiles 30–69
(Adults — FEV1 % pred 40–69)
Children: CF FEV1 percentiles b30
(Adults — FEV1 % pred b40)
Most report (over 80% sample) Most report (over 80% sample) Most report (over 80% sample)
Children Adults21 Children Adults21 Children Adults 21
Feel tired Tiredness
Disturbed sleep at night
Less energetic
Too tired to do anything.
Get out of breath when I do things.
Can't sleep at night (due to cough).
Fatigue
Disturbed sleep at night
Too tired to do anything— want to
lie down— no energy.
Get out of breath when I do things.
Sleep in day
Awake in night (due to cough and
difficulty breathing)
Fatigue
Sleep in day
Disturbed sleep at night (due to cough)
Decreased activities
Breathless: at rest/light activities
More effort to breath
Cough more Increased cough Cough more in day and night Increased cough Cough all the time
Hurts when I cough
Increased cough
More effort to cough
Chest pain
Sputum (thicker, darker) Increased sputum
(thicker, darker)
Increased Sputum (thicker, green)
Hurts to cough up
Increased Sputum (thicker, darker,
tastes nasty)
Difficult to cough up.
Nausea/vomiting (related to sputum/
coughing)
Decreased appetite Don't feel hungry Decreased appetite
Feel fed-up Miserable Miserable Miserable
Feel poorly
Body aches/hurts
Get a bad cold— runny nose,
sore throat, feel hot.
Feel unwell, General aches
Cold symptoms, runny nose
Sore throat.
Feel poorly
Body aches/hurts
Feel really poorly
Body aches/hurts
Many report (over 50% sample) Many report (over 50% sample) Many report (over 50% sample)
Too tired to do anything.
Can't sleep at night
Sleep in day
Can't breathe at night
Decreased activities.
Breathless with activities
Difficulty breathing at night
Get sputum/more sputum/get
yellow/green sputum
Sputum tastes nasty
Nausea/vomiting (related to sputum/
coughing)
Decrease appetite.
Decreased concentration
Don't feel hungry Decreased weight
General body aches
Chest aches/pain
Headaches
Hurts when cough
Get a bad cold— runny nose, sore throat.
Less frequently reported Less frequently reported Less frequently reported
Get sputum/more sputum/get
yellow/green sputum
Decreased weight Sputum tastes nasty.
Feel sick
Nausea/vomiting (related
to sputum/coughing)
Decreased weight.
Lose interest in appearance
Get out of breath when I do things Breathlessness Sleep in daytime Decreased concentration
Fed-up–don't feel hungry Headaches
General body aches
Chest ache/pain
Cold symptoms—sore throat
Get a bad cold— runny nose,
sore throat.
Headaches
General aches and pains
Runny nose
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Table 3
Child-reported symptoms of improvement from a pulmonary exacerbation by disease severity (most common phrases patients used to describe symptoms). Adult data
previously reported are inserted for comparison [21].
Mild Moderate Severe
Children: CF FEV1 percentiles ≥70
(Adults — FEV1 % pred ≥70)
Children: CF FEV1 percentiles 30–69
(Adults — FEV1 % pred 40–69)
Children: CF FEV1 percentiles b30
(Adults — FEV1 % pred b40)
Children Adults21 Children Adults21 Children Adults21
Most report (over 80% sample) Most report (over 80% sample) Most report (over 80% sample)
Can do more things
(go back to school,
play out, visit friends)
More energetic
(able to do
activities)
Can do more things
(go back to school, play
out, visit friends)
Able to do more
activities (in particular,
able to go back to
work/education)
Can do more things
(go back to school,
play out,
visit friends)
Able to do more
activities (e.g. go for
a walk, shopping,
able to use exercise bike)
Don't feel tired Less tired Loads more energy
Don't feel as tired
Less fatigue Have more energy
Don't feel as tired
Less fatigue
Better sleep Can sleep better Better sleep Can sleep better Better sleep
Don't cough as much Decreased cough
in day and night
Don't cough as much Decreased cough in day
and night
Don't cough as much
especially at night
Decreased cough
Less effort to cough
Less painful to cough
Less sputum
easier to
expectorate (thinner,
lighter colour)
Less sputum easier to
expectorate (thinner,
lighter colour)
Not as much sputum-
Not as much yellow/
green bits
Less sputum easier to
expectorate (thinner,
lighter colour, better
taste)
Happier Feel happier Happier Feel happier Happier
Easier to breath Improved appetite Can breathe better Less breathless
Less effort to breathe
Hurts less to breathe
Less frequently reported Less frequently reported Less frequently reported
Can breathe better Can breathe better especially at night
Don't cough in the night as much
Easier to breath
Not as much sputum
Less yellow/green bits
Not as much sputum
Less yellow/green bits
Improved appetite Feel more hungry Improved weight Feel more hungry Improved appetite
Improved weight
Improved
concentration
Less headaches
Less chest ache/pain
Less stress incontinence
Less headaches
Improved concentration
Less aches and pains
Less nausea/vomiting
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tion and monitor treatment progress across the cystic fibrosis life-
span. These results provide the rationale for the development of a
single scale for school age children and adults that could be sen-
sitive to progressive stages of CF disease.
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